NYSE:INO

Inovio Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy INO

*Your capital is at risk

$1.14

-0.0700 (-5.79%)

At Close: Jun 03, 2026

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

08:05am, Tuesday, 21'st Oct 2025

Publication includes complete data for all participants (n=39) up to week 72, further demonstrating durable and tolerable expression of DMAbs Effective target binding and confirmed functional activity

Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $8.80

01:14am, Monday, 20'th Oct 2025

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO - Get Free Report) have earned a consensus recommendation of "Hold" from the seven research firms that are presently covering the stock, MarketBeat.

INOVIO Reports Inducement Grant Under Inducement Plan

08:05am, Thursday, 02'nd Oct 2025

PLYMOUTH MEETING, Pa. , Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-r

INOVIO to Participate in Upcoming Scientific Conferences

08:05am, Thursday, 25'th Sep 2025

Several presentations to highlight key aspects of lead product candidate, INO-3107, as a potential treatment for Recurrent Respiratory Papillomatosis (RRP) Additional presentations focus on promise o

Inovio Pharmaceuticals, Inc. (INO) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)

09:37am, Friday, 05'th Sep 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 27th Annual Global Investment Conference September 5, 2025 7:00 AM EDT Company Participants Jacqueline Shea - CEO, President & Director Confe

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

11:01am, Thursday, 28'th Aug 2025

Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

08:05am, Tuesday, 26'th Aug 2025

Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U.S. Food and Drug Administration (FDA) by end of 2025 PLYMOUTH MEETING, Pa

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

08:05am, Monday, 25'th Aug 2025

PLYMOUTH MEETING, Pa. , Aug. 25, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-as

Inovio Pharmaceuticals, Inc. (INO) Q2 2025 Earnings Call Transcript

03:26am, Wednesday, 13'th Aug 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jacqueline E. Shea - CEO, President & Director Jennie Willson - Corporate Pa

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

04:05pm, Tuesday, 12'th Aug 2025

On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end Completed design verification (DV) testing of CELLECTRA® 5PSP device required

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

10:10am, Monday, 11'th Aug 2025

Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

08:05am, Monday, 11'th Aug 2025

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Ye

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by